Declining blood collection and utilization in the United States

Transfusion

Volumn 56, Issue 9, 2016, Pages 2184-2192

  Chung, Koo Whang ^a   Basavaraju, Sridhar V ^a   Mu, Yi ^b   van Santen, Katharina L ^b,c   Haass, Kathryn A ^a,d   Henry, Richard ^e   Berger, James ^e   Kuehnert, Matthew J ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CACI International Inc   (United States)

^d NORTHROP GRUMMAN CORPORATION   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHERESIS; BLOOD SAMPLING; CONFIDENCE INTERVAL; DISASTER; ERYTHROCYTE; HOSPITAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PLASMA; THROMBOCYTE TRANSFUSION; UNITED STATES;

EID: 84987615914     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13644     Document Type: Article

References (46)

1. Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010;304:1568-75.
2. Sherwood MW, Wang Y, Curtis JP, et al. Patterns and outcomes of red blood cell transfusion in patients undergoing percutaneous coronary intervention. JAMA 2014;311:836-43.
3. Bloch EM, Cohn C, Bruhn R, et al. A cross-sectional pilot study of blood utilization in 27 hospitals in Northern California. Am J Clin Pathol 2014;142:498-505.
4. Goodnough LT. Blood management: transfusion medicine comes of age. Lancet 2013;381:1791-2.
5. Goodnough LT, Shander A. Patient blood management. Anesthesiology 2012;116:1367-76.
6. Williamson LM, Devine DV. Challenges in the management of the blood supply. Lancet 2013;381:1866-75.
7. Drackley A, Newbold KB, Paez A, et al. Forecasting Ontario's blood supply and demand. Transfusion 2012;52:366-74.
8. The facts about whole blood: the national inventory trend [Internet]. Ottawa: Canadian Blood Services; 2015 [cited 2016 Jan 13]. Available from: https://www.blood.ca/en/bloodtype.
9. Borkent-Raven BA, Janssen MP, Van Der Poel CL. Demographic changes and predicting blood supply and demand in the Netherlands. Transfusion 2010;50:2455-60.
10. TRIP annual report. Hemovigilance. 2013 extended version [Internet]. Leiden: Transfusion and Transplantation Reactions in Patients (TRIP) National Hemovigilance Office; 2015 [cited 2016 Jan 13]. Available from: http://www.tripnet.nl/pages/en/documents/TRIP2013Hemovigilance-English.pdf.
11. Janssen MP, van Hoeven LR, Rautmann G. Trends and observations on the collection, testing and use of blood and blood components in Europe 2001-2011 report. Strasbourg: Council of Europe; 2015.
12. Latest stocks and statistics [Internet]. London: National Health Service Blood and Transplant (NHSBT); 2015 [cited 2016 Jan 13]. Available from: http://www.blood.co.uk/about-blood/stock-levels-statistics/.
13. Harvey AR, Basavaraju SV, Chung KW, et al. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 2015;55:709-18.
14. Kamp C, Heiden M, Henseler O, et al. Management of blood supplies during an influenza pandemic. Transfusion 2010;50:231-9.
15. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998;38:625-36.
16. Sullivan MT, Cotten R, Read EJ, et al. Blood collection and transfusion in the United States in 2001. Transfusion 2007;47:385-94.
17. National blood collection & utilization survey [Internet]. Washington (DC): US Department of Health and Human Services; 2015 [cited 2015 Aug 21]. Available from: http://www.hhs.gov/ash/bloodsafety/nbcus/.
18. FDA. Blood establishment registration database [Internet]. Silver Spring (MD): US Food and Drug Administration; 2015 [cited 2016 Jan 13]. Available from: https://www.accessdata.fda.gov/scripts/cber/CFAppsPub/.
19. US Census Bureau. Population and housing unit estimates [Internet]. Washington (DC): US Department of Commerce; 2015 [cited 2016 Jan 13]. Available from: http://www.census.gov/popest/index.html.
20. The 2011 National Blood Collection and Utilization Survey report. Washington (DC): US Department of Health and Human Services; 2013.
21. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken (NJ): Wiley; 2004.
22. Heitjan DF, Roderick JA. Multiple imputation for the fatal accident reporting system. J R Stat Soc Ser C Appl Stat 1991;40:13-29.
23. Schenker N, Taylor JM. Partially parametric techniques for multiple imputation. Comput Stat Data Anal 1996;22:425-46.
24. He Y, Raghunathan TE. Tukey's gh distribution for multiple imputation. Am Stat 2006;60:251-6.
25. Woodruff RS. A simple method for approximating the variance of a complicated estimate. J Am Stat Assoc 1971;66:411-4.
26. Fuller WA. Regression analysis for sample survey. Sankhya Ser C 1975;37:117-32.
27. Pathak R, Bhatt VR, Karmacharya P, et al. Trends in blood-product transfusion among inpatients in the United States from 2002 to 2011: data from the Nationwide Inpatient Sample. J Hosp Med 2014;9:800-1.
28. Goodnough LT, Maggio P, Hadhazy E, et al. Restrictive blood transfusion practices are associated with improved patient outcomes. Transfusion 2014;54:2753-9.
29. Ruiz-Argüelles GJ, López-Martinez B, Gómez-Rangel D, et al. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience. Hematology 2003;8:151-4.
30. Scheinberg P, Nunez O, Wu C, et al. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006;133:606-11.
31. Woo YJ, Nacke EA. Robotic minimally invasive mitral valve reconstruction yields less blood product transfusion and shorter length of stay. Surgery 2006;140:263-7.
32. Hasley PB, Lave JR, Kapoor WN. The necessary and the unnecessary transfusion: a critical review of reported appropriateness rates and criteria for red cell transfusions. Transfusion 1994;34:110-5.
33. Triulzi D, Gottschall J, Murphy E, et al. A multicenter study of plasma use in the United States. Transfusion 2015;55:1313-9; quiz 1312.
34. Likosky DS, Al-Attar PM, Malenka DJ, et al. Geographic variability in potentially discretionary red blood cell transfusions after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2014;148:3084-9.
35. Schiergens TS, Rentsch M, Kasparek MS, et al. Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Dis Colon Rectum 2015;58:74-82.
36. Rohde JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014;311:1317-26.
37. Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012;52 Suppl 1:65S-79S.
38. Shander A, Javidroozi M. Strategies to reduce the use of blood products: a US perspective. Curr Opin Anaesthesiol 2012;25:50-8.
39. Tinegate H, Chattree S, Iqbal A, et al. Ten-year pattern of red blood cell use in the North of England. Transfusion 2013;53:483-9.
40. van Hoeven L, Janssen MP, Rautmann G. The collection, testing and use of blood and blood components in Europe. Strasbourg: Concil of Europe; 2012.
41. Advisory Committee on Blood and Tissue Safety Availability. Recommendations of the 47th meeting of the ACBTSA, November 2015 [Internet]. Washington, DC: US Department of Health & Human Services; 2015 [cited 2016 Feb 16]. Available from: http://www.hhs.gov/ash/bloodsafety/advisorycommittee/recommendations/nov2015-recommendations.html.html.
42. Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply—time to raise the bar. N Engl J Med 2015;373:882.
43. FDA approves first pathogen reduction system to treat plasma [Internet]. Silver Spring (MD): US Food and Drug Administration; 2014 [cited 2016 Jan 13].
44. Bacterial detection testing by blood and blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion [Internet]. Silver Spring (MD): US Food and Drug Administration; 2014 [cited 2016 Apr 18]. Available from: https://www.federalregister.gov/articles/2014/12/09/2014-28809/bacterial-detection-testing-by-blood-collection-establishments-and-transfusion-services-to-enhance.
45. Strategies for implementation of antibody and nucleic acid-based testing for Babesia microti in blood donors [Internet]. Silver Spring (MD): US Food and Drug Administration; 2015 [cited 2016 Apr 18]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM446274.pdf.
46. Wallace EL, Surgenor DM, Hao HS, et al. Collection and transfusion of blood and blood components in the United States, 1989. Transfusion 1993;33:139-44.